Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02164812 · ClinicalTrials.gov registry record · Phase 1
Study to Determine the Effect of Efavirenz on the ECG QTcF Interval in Healthy Subjects
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 58
- Enrollment target
NCT02164812 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 58 participants.
The verdict
NCT02164812, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 58 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether multiple doses of Efavirenz has an effect on the QTc interval (corrected by Fridericia) in CYP2B6 \*1/\*6 and \*6/\*6 healthy subjects.
Interventions
- DRUG Placebo
- DRUG Moxifloxacin
- DRUG Efavirenz
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2014-07 |
| Est. Completion | 2015-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02164812
The ClinicalTrials.gov registry entry for NCT02164812 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02164812 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02164812 about?
NCT02164812 is a clinical study titled "Study to Determine the Effect of Efavirenz on the ECG QTcF Interval in Healthy Subjects". The purpose of this study is to determine whether multiple doses of Efavirenz has an effect on the QTc interval (corrected by Fridericia) in CYP2B6 \*1/\*6 and \*6/\*6 healthy subjects.
What is the current status of trial NCT02164812?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 58 participants. The study started on 2014-07. Estimated completion is 2015-08.
What interventions are being tested in trial NCT02164812?
The interventions under investigation include: Placebo (DRUG), Moxifloxacin (DRUG), Efavirenz (DRUG).
Who is sponsoring clinical trial NCT02164812?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.